Singapore is one of Asia's most important biomedical and pharmaceutical hubs. Singapore has been able to attract both international and private investors who have driven the industry forward thanks to the government's Biomedical Sciences (BMS) project, which was launched in June 2000.
Singapore is the preferred place for enterprises to research and create new goods that better fulfil Asia’s healthcare demands since it is a major biomedical sciences cluster in the heart of Asia. Our pro-business environment, infrastructure, talent, and innovation ecosystem, as well as our proximity to the rest of Asia, all help businesses. Pharmaceutical and biotechnology companies have set up shop in Singapore to service patients from all over the world and connect with the booming Asian market, thanks to the city-large state’s pool of trained manpower, robust manufacturing capabilities, and dynamic research ecosystem.
Many best-in-class manufacturing facilities are located in Singapore, where a diverse range of goods, including small molecules, biologics, cell therapy, and medical nutrition, are launched and manufactured. GSK, Merck Sharp & Dohme (“MSD”), Pfizer, Novartis, Roche, Sanofi, AbbVie, and Amgen are among the top ten pharmaceutical corporations with production facilities in Singapore.
Singapore has made significant investments in infrastructure to assist pharmaceutical businesses in establishing manufacturing operations in the city-state, including ready-built facilities and innovative partnerships.
Start-up Ecosystem Growing
Singapore is building on the foundation of Big Pharma businesses to strengthen the biotech community through finance and commercialization interventions in order to generate a globally competitive and inventive biomedical sector.
In 2018, the Singapore government established the National Research Fund (“NRF”)-Temasek IP commercialization vehicle to assist Singapore-based biotechs in their commercialization activities. The fund co-invests in start-ups whose business models are based on intellectual property developed through publically supported research.
